April.2019-March.2020
-
21/1/2020Announcement of the First Patient In for Phase I study of OTSA101 in Japanese patients with synovial sarcoma
-
16/1/2020Announcement of milestone payment for the progress of Phase III clinical trial of the cancer-specific peptide vaccine S-588410
-
23/12/2019Announcement of executing license agreement with Nobelpharma Co., Ltd.
-
5/11/2019Announcement of additional sequencing services at our subsidiary company, Cancer Precision Medicine, Inc. (CPM)
-
1/10/2019Announcement of the presentation of results for exploratory study of peptide vaccine S-588410 at European Society for Medical Oncology 2019 Congress
-
15/8/2019Announcement of the initiation of Phase I study for OTSA101 in Japanese patients with synovial sarcoma
-
18/6/2019Announcement of executing license agreement with Thyas Co., Ltd.
back to top